TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11864664

Group type: EXPERIMENTAL
Intervention: Soy isoflavone 100 mg daily for 4 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 10715910

Group type: EXPERIMENTAL
Intervention: Misoprostol (Cytotec‐Searle) vaginally (group M, n = 30)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Oxytocin (group Ox, n = 34)
Number of subjects: 64
Study: 7566021

Group type: EXPERIMENTAL
Intervention: Margarine containing sitostanol ester (1.8 or 2.6 g of sitostanol per day)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control group (margarine without sitostanol ester)
Number of subjects: 153
Study: 2090399

Group type: EXPERIMENTAL
Intervention: Bendazac lysine (anti-cataract drug)
Number of subjects: 43
Study: 345462

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study: 31299087

Group type: EXPERIMENTAL
Intervention: Clinically apparent AKs
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: AKs
Number of subjects: 26
Study: 28024935

Group type: COMPARATOR
Intervention: Nitrate (140 mL·day−1 NO3−‐rich beetroot juice, 8.4 mmol NO3−·day−1)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Nitrate + Iodide (140 mL·day−1 NO3−‐rich beetroot juice and 450 μg potassium iodide·day−1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nitrate + Iodide
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nitrate
Number of subjects: 9
Study: 25896114

Group type: EXPERIMENTAL
Intervention: Supervised exercise videogames (EVGs) for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supervised standard exercise for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition for 12 weeks
Number of subjects: 0
Study: 23555873

Group type: EXPERIMENTAL
Intervention: Rhythmic visual stimulation at 10.6 Hz
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rhythmic visual stimulation at control frequencies (3.9 Hz, 7.1 Hz, 14.2 Hz)
Number of subjects: 0
Study: 20634036

Group type: EXPERIMENTAL
Intervention: Wound drain (Group B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No wound drain (Group A)
Number of subjects: 100
Study: 19363857

Group type: EXPERIMENTAL
Intervention: CLIN/RA (clindamycin 1.2% and tretinoin 0.025%)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 0.1% tretinoin gel
Number of subjects: 45

Group type: COMPARATOR
Intervention: 0.1% adapalene gel
Number of subjects: 45
Study: 16709386

Group type: EXPERIMENTAL
Intervention: Levosimendan (loading dose of 12 microg/kg followed by 24-hour infusion of 0.2 microg/kg per min)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Dobutamine (24-hour infusion of 7.5 microg/kg per min)
Number of subjects: 41
Study: 15298561

Group type: EXPERIMENTAL
Intervention: Mite-impermeable mattress encasings and educational package
Number of subjects: 696

Group type: COMPARATOR
Intervention: Control group (basic information about allergies)
Number of subjects: 696
Study: 11776446

Group type: EXPERIMENTAL
Intervention: 4.0 J/cm2 treatment group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1.7 J/cm2 treatment group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 40
Study: 9621294

Group type: EXPERIMENTAL
Intervention: OTZ (0.5 g three times a day orally with meals)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7943083

Group type: EXPERIMENTAL
Intervention: 100% oxygen for 20 minutes
Number of subjects: 20

Group type: COMPARATOR
Intervention: 40% oxygen for 20 minutes
Number of subjects: 20

Group type: COMPARATOR
Intervention: 40% oxygen for 45 minutes
Number of subjects: 20
Study: 3591872

Group type: EXPERIMENTAL
Intervention: Intracameral acetylcholine during the operative procedure
Number of subjects: 36

Group type: COMPARATOR
Intervention: Balanced salt solution
Number of subjects: 36
Study: 31560066

Group type: EXPERIMENTAL
Intervention: Apalutamide (240 mg daily)
Number of subjects: 1207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1207
Study: 29198449

Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg once daily for 14 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oral contraceptive alone (reference)
Number of subjects: 24
Study: 27092703

Group type: EXPERIMENTAL
Intervention: Active CPAP
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 40
Study: 25303114

Group type: EXPERIMENTAL
Intervention: Data mining approach to post-stroke mortality prediction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistically significant risk factors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predictive classification models
Number of subjects: 0
Study: 21747129

Group type: EXPERIMENTAL
Intervention: Bilateral electric breast pumping
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Hand expression
Number of subjects: 68

Group type: COMPARATOR
Intervention: Breast pumping
Number of subjects: 68
Study: 20231298

Group type: EXPERIMENTAL
Intervention: Irinotecan plus cisplatin (IP)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Etoposide plus cisplatin (EP)
Number of subjects: 405
Study: 18166828

Group type: EXPERIMENTAL
Intervention: Fast Track intervention
Number of subjects: 0
Study: 15266201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Innovative research designs and psychosocial treatments
Number of subjects: 0
Study: 11124288

Group type: EXPERIMENTAL
Intervention: Timolol maleate
Number of subjects: 28

Group type: COMPARATOR
Intervention: Timolol hemihydrate
Number of subjects: 28
Study: 9357184

Group type: EXPERIMENTAL
Intervention: Metronidazole (400 mg tid for 10 days, followed by placebo for 50 days)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Isapghul (10 g bid for 60 days)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (1 capsule bid for 60 days)
Number of subjects: 45
Study: 8479248

Group type: EXPERIMENTAL
Intervention: Cumulative fraction absorbed‐time profile method of paracetamol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proportional area under the curve method of paracetamol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisapride, codeine, and metoclopramide with neostigmine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisapride, codeine, and metoclopramide without neostigmine
Number of subjects: 0
Study: 3083092

Group type: EXPERIMENTAL
Intervention: Intravenous 1‐mg dose of leuprolide
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Subcutaneous 1‐mg dose of leuprolide
Number of subjects: 6

Group type: COMPARATOR
Intervention: Comparison of intravenous and subcutaneous administration
Number of subjects: 6
Study: 3671256

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High altitude (4846 m)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Exercise test maintaining heart rate at 85% of maximum for 15 minutes
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 18
Study: 31058342

Group type: EXPERIMENTAL
Intervention: Continuous-care model
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study: 28487089

Group type: EXPERIMENTAL
Intervention: 2-incision THA
Number of subjects: 71

Group type: COMPARATOR
Intervention: mini-posterior THA
Number of subjects: 71
Study: 26152248

Group type: EXPERIMENTAL
Intervention: Cannulated screws
Number of subjects: 58

Group type: COMPARATOR
Intervention: Dynamic hip screw (DHS)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study: 23316876

Group type: EXPERIMENTAL
Intervention: Oral (PO) therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 60
Study: 21971723

Group type: EXPERIMENTAL
Intervention: Right lateral decubitus position
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Left lateral decubitus position
Number of subjects: 8
Study: 18378313

Group type: EXPERIMENTAL
Intervention: Observation (n = 595)
Number of subjects: 1191

Group type: COMPARATOR
Intervention: Medication (n = 596)
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: Topical prostaglandin analogues (PGAs)
Number of subjects: 1191
Study: 17234108

Group type: EXPERIMENTAL
Intervention: XP-828L 5 g/d for 56 days
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 15332397

Group type: COMPARATOR
Intervention: Fixed CPAP
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: AutoSet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Horizon
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Virtuoso
Number of subjects: 12
Study: 10999439

Group type: EXPERIMENTAL
Intervention: Ginseng-treated group (7 patients)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Non-treated group (10 patients)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (10 normotensive subjects)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside infusion
Number of subjects: 17
Study: 9540780

Group type: EXPERIMENTAL
Intervention: Oral anticoagulant (INR 2.5)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Subcutaneous calcium heparin 0.2 ml bid (8.00 and 20.00)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Subcutaneous calcium heparin (0.5 ml at 20.00)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Elastic TED stockings (Control group)
Number of subjects: 177
Study: 8112905

Group type: EXPERIMENTAL
Intervention: ST-depression in ECG at rest
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Combination of ST-depression and low maximal work load
Number of subjects: 190

Group type: COMPARATOR
Intervention: More sophisticated methods of evaluating the ECG reaction during exercise
Number of subjects: 190
Study: 3036936

Group type: EXPERIMENTAL
Intervention: recombinant alpha‐2 interferon
Number of subjects: 383

Group type: COMPARATOR
Intervention: no treatment (control)
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: interferon
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: adriamycin
Number of subjects: 383
Study: 29481395

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no botulinum toxin type A)
Number of subjects: 14
Study: 27089927

Group type: EXPERIMENTAL
Intervention: Home-exercise intervention (12 months, prescribed in 10 visits from a physiotherapist)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 340
Study: 26669766

Group type: EXPERIMENTAL
Intervention: Gentle assisted pushing (GAP) in the upright posture
Number of subjects: 1145

Group type: EXPERIMENTAL
Intervention: Upright posture only
Number of subjects: 1145

Group type: COMPARATOR
Intervention: Routine practice (recumbent/supine posture)
Number of subjects: 1145
Study: 22300334

Group type: EXPERIMENTAL
Intervention: Coping with stress training program
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 14
Study: 20684894

Group type: EXPERIMENTAL
Intervention: Pain physiology education
Number of subjects: 48

Group type: COMPARATOR
Intervention: Pacing and self-management education
Number of subjects: 48
Study: 18331150

Group type: EXPERIMENTAL
Intervention: Active intervention (specific details not provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monte Carlo simulations
Number of subjects: 0
Study: 16329131

Group type: EXPERIMENTAL
Intervention: Coping skills intervention (standard care plus three visits to teach coping skills)
Number of subjects: 354

Group type: COMPARATOR
Intervention: Standard hospice care plus three supportive visits
Number of subjects: 354

Group type: COMPARATOR
Intervention: Standard hospice care
Number of subjects: 354
Study: 14658256

Group type: EXPERIMENTAL
Intervention: Indomethacin administration
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standard therapy without indomethacin
Number of subjects: 65
Study: 10919934

Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 76

Group type: COMPARATOR
Intervention: No Exercise Training (NT)
Number of subjects: 76
Study: 8923361

Group type: EXPERIMENTAL
Intervention: Sulfasalazine (target dosage, 40 mg/kg/day)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Auranofin (6‐9 mg/day)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Sulfasalazine (after excluding patients previously treated with i.m. gold)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Auranofin
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Number of subjects: 200
Study: 1399378

Group type: EXPERIMENTAL
Intervention: Omeprazole, 40 mg o.m., for 10 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3888030

Group type: EXPERIMENTAL
Intervention: 40 mg sodium fluoride daily
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 31666897

Group type: EXPERIMENTAL
Intervention: Kinect training (Group II)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Non-participants in Kinect training (Group I)
Number of subjects: 68
Study: 30233000

Group type: EXPERIMENTAL
Intervention: Balanced Crystalloid (Plasmalyte)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Normal Saline
Number of subjects: 44
Study: 27299909

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral self-help manual
Number of subjects: 54

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 54
Study: 25523634

Group type: EXPERIMENTAL
Intervention: Weekly low-dose methotrexate (MTX) as an add-on therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 0
Study: 21990524

Group type: EXPERIMENTAL
Intervention: Digital subtraction angiography (DSA) in group A (with IVH)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Digital subtraction angiography (DSA) in group B (without IVH)
Number of subjects: 293
Study: 19820870

Group type: EXPERIMENTAL
Intervention: Preservation of the medial pectoral nerve (MPN)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sectioning of the medial pectoral nerve (MPN)
Number of subjects: 30
Study: 17454467

Group type: EXPERIMENTAL
Intervention: Lidocaine (10 ml 2% lidocaine) injected down the drain before removal
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional drain removal (no lidocaine)
Number of subjects: 36
Study: 14997327

Group type: EXPERIMENTAL
Intervention: High UVR exposure group
Number of subjects: 201

Group type: COMPARATOR
Intervention: Skin cancer patients
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Age-related increase in LEP(u/l)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: UVR exposure data collection methods
Number of subjects: 201
Study: 11361048

Group type: EXPERIMENTAL
Intervention: CS-866 (oral administration)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: RNH-6270 (intravenous administration)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: CS-866 (up to 160 mg/day)
Number of subjects: 104
Study: 9732337

Group type: EXPERIMENTAL
Intervention: Tight blood pressure control aiming at <150/85 mm Hg (using captopril or atenolol)
Number of subjects: 1148

Group type: COMPARATOR
Intervention: Less tight control aiming at <180/105 mm Hg
Number of subjects: 1148
Study: 7803318

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (16 sessions over a six-month period)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 3044092

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30916626

Group type: EXPERIMENTAL
Intervention: Penile traction therapy with RestoreX device for 30 to 90 minutes per day
Number of subjects: 110

Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 110
Study: 28392547

Group type: EXPERIMENTAL
Intervention: Highest quartile of toenail chromium (TCL)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus (DM) group
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Non-DM group
Number of subjects: 288
Study: 27079599

Group type: EXPERIMENTAL
Intervention: Icare PRO rebound tonometry
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tono-Pen XL tonometry
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bland-Altman analysis
Number of subjects: 30
Study: 25133997

Group type: EXPERIMENTAL
Intervention: Total body resistance exercise intervention (TOTRX)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Lumbar extensor exercise intervention (LEXT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 49
Study: 22237835

Group type: COMPARATOR
Intervention: Gemcitabine 1 g/m2 weekly on days 1, 8, and 15 (arm A)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PEFG regimen (cisplatin and epirubicin 40 mg/m2, day 1; gemcitabine 600 mg/m2, days 1, 8; 5-fluorouracil 200 mg/m2 daily, days 1-28) (arm B)
Number of subjects: 100
Study: 19876729

Group type: EXPERIMENTAL
Intervention: Early cavitating blastocysts
Number of subjects: 576

Group type: COMPARATOR
Intervention: Deflated expanded blastocysts
Number of subjects: 576
Study: 17362049

Group type: COMPARATOR
Intervention: Sipuleucel-T (APC8015)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various immunotherapy approaches (including dendritic cell vaccination, whole cell vaccines, and recombinant viral vectors)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy (taxane- and platinum-compound-based)
Number of subjects: 0
Study: 15894038

Group type: EXPERIMENTAL
Intervention: 2.5% glycyrrhetinic acid cream (n=9)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo cream (n=9)
Number of subjects: 18
Study: 12080401

Group type: EXPERIMENTAL
Intervention: Prototype beta‐glucan cereal (8.1 g% beta‐glucan)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Beta‐glucan bar (6.5 g% beta‐glucan)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Commercial oat bran breakfast cereal (4.4 g% beta‐glucan)
Number of subjects: 16

Group type: COMPARATOR
Intervention: White bread
Number of subjects: 16
Study: 9650129

Group type: EXPERIMENTAL
Intervention: Early induction group (induction the following morning after PROM)
Number of subjects: 1385

Group type: COMPARATOR
Intervention: Late induction group (induction two days later)
Number of subjects: 1385

Group type: EXPERIMENTAL
Intervention: Short latency group (contractions started within 2 hours after admission)
Number of subjects: 1385
Study: 9471593

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 2019667

Group type: EXPERIMENTAL
Intervention: Etoposide (600 mg/m2) + Cisplatin (100 mg/m2) administered intraperitoneally
Number of subjects: 6
Study: 7078417

Group type: EXPERIMENTAL
Intervention: ZnSO4 (100 mg/day Zn++)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 30821349

Group type: COMPARATOR
Intervention: Propofol infusion at 50-150 μg/kg/min (Group P)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine bolus of 1 μg/kg followed by infusion at 0.5-1.0 μg/kg/hr (Group D)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Propofol (Group P)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Group D)
Number of subjects: 60
Study: 31487546

Group type: COMPARATOR
Intervention: Usual care (standard training)
Number of subjects: 1460

Group type: EXPERIMENTAL
Intervention: Smartphone (tailored behavioral communication, using smartphone technology)
Number of subjects: 1460

Group type: EXPERIMENTAL
Intervention: Paper-based (tailored behavioral communication, using paper-based tools)
Number of subjects: 1460
Study: 28893432

Group type: EXPERIMENTAL
Intervention: Person-centred care (PCC) intervention for six months
Number of subjects: 199
Study: 25283723

Group type: EXPERIMENTAL
Intervention: Training with problem representation transfer (nested sets)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Training with format shift to natural frequencies
Number of subjects: 0
Study: 25047499

Group type: EXPERIMENTAL
Intervention: Child school/daycare functioning
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Fear of hypoglycaemia
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes-related quality of life
Number of subjects: 134
Study: 23177894

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (Zn)
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: Zinc and copper supplementation (Zn + Cu)
Number of subjects: 808

Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 808
Study: 21596680

Group type: EXPERIMENTAL
Intervention: Immediate ART (zidovudine, lamivudine, efavirenz) started at study entry
Number of subjects: 253

Group type: COMPARATOR
Intervention: Deferred ART (zidovudine, lamivudine, efavirenz) started 2 months after randomization
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Immediate ART
Number of subjects: 253

Group type: COMPARATOR
Intervention: Deferred ART
Number of subjects: 253
Study: 19159002

Group type: EXPERIMENTAL
Intervention: Five-week education intervention including a two-hour training session once a week for five weeks
Number of subjects: 137
Study: 16777649

Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy (CST)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 201
Study: 15085366

Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (IFG)
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus (DM)
Number of subjects: 906

Group type: COMPARATOR
Intervention: No diabetes mellitus (no DM)
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Advanced atherosclerosis
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Coronary artery disease without peripheral stenosis
Number of subjects: 906
Study: 11777176

Group type: EXPERIMENTAL
Intervention: Intravenous prostaglandin E1 (PGE1)
Number of subjects: 2
Study: 10204645

Group type: EXPERIMENTAL
Intervention: Hospital stroke diagnoses
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Underlying cause of death
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Data review
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Trial supplementation with alphatocopherol or beta-carotene
Number of subjects: 546
Study: 7851515

Group type: EXPERIMENTAL
Intervention: Cerebellar patients adapting pinch force levels to different object loads
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cerebellar patients
Number of subjects: 21